Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

被引:83
|
作者
Ganbaatar, Byambasuren [1 ]
Fukuda, Daiju [2 ]
Shinohara, Masakazu [3 ,4 ]
Yagi, Shusuke [1 ]
Kusunose, Kenya [1 ]
Yamada, Hirotsugu [5 ]
Soeki, Takeshi [1 ]
Hirata, Ken-ichi [6 ]
Sata, Masataka [1 ]
机构
[1] Tokushima Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Cardiodiabet Med, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[5] Tokushima Univ, Dept Community Med Cardiol, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[6] Kobe Univ, Div Cardiovasc Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan
关键词
Atherosclerosis; Inflammation; Endothelial function; SGLT2; inhibitor; Empagliflozin; PERIVASCULAR ADIPOSE-TISSUE; SGLT2; INHIBITOR; MORTALITY; ATHEROSCLEROSIS; PHENOTYPE; DISEASE; ROLES; AGES;
D O I
10.1016/j.ejphar.2020.173040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE(-/-)) mice. Male streptozotocin (STZ) - induced diabetic ApoE(-/-) mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE / mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E-2 and thromboxane B-2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-alpha in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE(-/-) mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein
    Van De Parre, Tim J. L.
    Guns, Pieter-Jan D. F.
    Fransen, Paul
    Martinet, Wim
    Bult, Hidde
    Herman, Arnold G.
    De Meyer, Guido R. Y.
    ATHEROSCLEROSIS, 2011, 216 (01) : 54 - 58
  • [22] Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice
    Tomoya Hara
    Daiju Fukuda
    Byambasuren Ganbaatar
    Phuong Tran Pham
    Kunduziayi Aini
    Arief Rahadian
    Kumiko Suto
    Shusuke Yagi
    Kenya Kusunose
    Hirotsugu Yamada
    Takeshi Soeki
    Masataka Sata
    Heart and Vessels, 2023, 38 : 1386 - 1394
  • [23] Cognitive dysfunction and neurochemical impairments of apolipoprotein E-deficient mice
    Michaelson, DM
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S2 - S2
  • [24] Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice
    Mita, Tomoya
    Otsuka, Aiko
    Azuma, Kosuke
    Uchida, Toyoyoshi
    Ogihara, Takeshi
    Fujitani, Yoshio
    Hirose, Takahisa
    Mitsumata, Masako
    Kawamori, Ryuzo
    Watada, Hirotaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 358 (03) : 679 - 685
  • [25] DIETARY VITAMIN A DEFICIENCY ACCELERATES ATHEROGENESIS IN YOUNG APOLIPOPROTEIN E-DEFICIENT MICE
    Harari, Ayelet
    Harats, Dror
    Ben-Amotz, Ami
    Kamari, Yehuda
    Shaish, Aviv
    ATHEROSCLEROSIS, 2017, 263 : E166 - E166
  • [26] Functional blockage of EMMPRIN ameliorates atherosclerosis in apolipoprotein E-deficient mice
    Liu, Hong
    Yang, Li-xia
    Guo, Rui-wei
    Zhu, Guo-Fu
    Shi, Yan-Kun
    Wang, Xian-mei
    Qi, Feng
    Guo, Chuan-ming
    Ye, Jin-shan
    Yang, Zhi-hua
    Liang, Xing
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 3248 - 3253
  • [27] A selective mineralocorticoid receptor blocker, esaxerenone, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein e-deficient mice
    Munkhjargal, U.
    Daiju, F.
    Masataka, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [28] Inhibition of S1P2 receptor ameliorates endothelial dysfunction and prevents atherogenesis in apolipoprotein-E-deficient Mice
    Ganbaatar, B.
    Fukuda, D.
    Yagi, S.
    Soeki, T.
    Sata, M.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1404 - 1404
  • [29] Serum Amyloid A Stimulates Atherogenesis and Renal Dysfunction in Apolipoprotein E-Deficient Mice Fed a Normal Chow Diet
    Witting, Paul
    Chami, Belal
    Hambly, Thomas
    Wang, XiaoSuo
    Fong, Genevieve
    Dennis, Joanne
    FREE RADICAL BIOLOGY AND MEDICINE, 2016, 100 : S154 - S154
  • [30] Chronic treatment with the hexapeptide angiotensin IV improves endothelial dysfunction in apolipoprotein E-deficient mice
    Vinh, A
    Gaspari, TA
    Widdop, RE
    CIRCULATION, 2005, 112 (17) : U369 - U370